The management of erectile dysfunction has been transformed since the first oral phosphodiesterase type 5 (PDE-5) inhibitor sildenafil (Viagra®) was approved in the late 1990s. The PDE-5 inhibitors developed subsequently (tadalafil [Cialis®] and vardenafil [Levitra®]) differ in important ways from their predecessor. Here, Alberto Briganti and his colleagues compare and contrast the pharmacokinetics, pharmacodynamics, safety and efficacy of these three drugs.
- Alberto Briganti
- Andrea Salonia
- Francesco Montorsi
